ClinicalTrials.gg
RecruitingNCT07861035HEART-1Updated Oct 6, 2026

A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy

A Phase 1 interventional study of HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells) and HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells) in Ischemic Cardiomyopathy, sponsored by HieraBio Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by HieraBio Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Sep 2026).
  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
19 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 148 studies in Heart Failure with a site in Korea, Republic of — 48 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.

Planned enrollment
104th of 109
12 · median 227
Started
2026
with 17 others
Phase 1
8 of 148
3 open now
Primary completion
2027-10
later than 21 of 53 live
Registered
147th of 148
by date

Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 104th largest by planned enrollment of the 109 interventional ones that give a count, is one of 18 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 21 of the 53 other live ones, and was the 147th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

48 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 19 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Heart Failure with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Ischemic cardiomyopathy occurs when the heart muscle is permanently weakened due to blocked coronary arteries that limit blood flow. Current treatments, including medications and lifestyle changes, can manage symptoms but cannot restore the damaged heart muscle.

Stem cell therapy offers a promising approach to repair and regenerate damaged heart tissue. This study will evaluate the safety and tolerability of HB1011 - an allogeneic myocardium-derived mesenchymal stem cell therapy - in patients with ischemic cardiomyopathy who are undergoing coronary artery bypass grafting (CABG) surgery. HB1011 will be injected directly into the damaged heart muscle during the CABG procedure. Participants will receive different doses of HB1011, starting from a lower dose and gradually increasing, to identify the safest and most appropriate dose for future studies.

Read the detailed description

Participation in this study will last approximately 12 months following treatment. Prior to surgery, potential participants will undergo a screening visit to confirm eligibility. Screening assessments will include a physical exam, review of medical history and current medications, blood tests, electrocardiogram (ECG), echocardiogram, and cardiac MRI. Eligible participants will be admitted to the hospital 1 to 2 days before their scheduled CABG surgery for final pre-operative assessments.

On the day of surgery, CABG will be performed as planned. Once the bypass procedure is complete and before chest closure, HB1011 will be injected directly into the damaged heart muscle through a transepicardial approach. Participants will be assigned to either a low-dose or high-dose group following a sequential dose-escalation design, with safety carefully monitored at each stage before proceeding to the next dose level. After receiving the injections, participants will remain hospitalized for post-operative monitoring and observation.

Following discharge, participants will return for scheduled outpatient visits at 1, 3, 6, 9, and 12 months after surgery. At each visit, safety and tolerability will be assessed through physical exams, blood tests, and cardiac evaluations. Exploratory assessments of heart function, including echocardiogram and cardiac MRI, will be performed at selected time points to evaluate any changes over the course of the study.

03

Conditions studied

  • Ischemic Cardiomyopathy

Browse trials for

Keywords

  • Ischemic cardiomyopathy
  • Allogeneic Mesenchymal Stem Cells
  • Myocardium-derived Stem Cells
  • Cardiac Stem Cell
  • Coronary Artery Bypass Grafting
  • CABG
  • Intramyocardial
  • Transepicardial
  • Cell-based Therapy
  • Phase I Clinical Trial
  • Heart Failure
04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled to undergo coronary artery bypass grafting (CABG) surgery
  • (LVEF) ≤ 40%
  • Age 19 to 85 years, male or female
  • Diagnosed with ischemic cardiomyopathy
  • functional Class II-IV at screening
  • Ability to understand the study and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • New myocardial infarction within 28 days prior to screening, or unstabilized cardiac enzyme levels at screening
  • Participation in another clinical trial involving an drug or device within 6 months prior to screening
  • to cardiac MRI (e.g., pacemaker, severe claustrophobia)
  • Pregnant, breastfeeding, or unwilling to use adequate during the study
  • History of within 5 years, severe allergic reaction, prior cardiac surgery (including CABG), stroke within 3 months, or incomplete recovery from major surgery within 12 weeks
  • Significant comorbidities at screening, including severe ventricular arrhythmia, uncontrolled atrial fibrillation, severe or unstable , congenital heart disease, active viral or severe infection, disease, or active tuberculosis
  • Active , , or infection
  • Systemic therapy at protocol-defined high doses, or high-dose short-term therapy within 4 weeks prior to treatment
  • Suspected active infection within 48 hours before surgery
  • less than 1 year due to non-cardiac conditions
  • Requirement for concomitant major cardiac or aortic procedures at the time of CABG (e.g., valve repair/replacement, aortic surgery)
  • Severe chronic renal impairment ( \< 30 mL/min/1.73m²), renal replacement therapy, or significant hepatic disease
  • Hemodynamically unstable patients
  • Severe pulmonary hypertension or conditions requiring resting oxygen therapy
  • Panel reactive antibody (PRA) Class I or II ≥ 50%
  • > 10% in patients with diabetes
  • Severe peripheral arterial disease with rest pain, ischemic ulcer, or gangrene
  • to bovine-derived proteins
  • Any other condition deemed unsuitable for participation by the investigator
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Group 1: Low Dose of HB1011

    Drug: HB1011 (0.5 × 10⁷ cells), transepicardial intramyocardial injection at the time of CABG

    Biological: HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)

  • Experimental
    Group 2: High Dose of HB1011

    Drug: HB1011 (1.0 × 10⁷ cells), transepicardial intramyocardial injection at the time of CABG

    Biological: HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)

Interventions

  • BiologicalHB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)

    Biological: Lower dose of HB1011 injection Participants will receive between 5 intramyocardial injections of 1 million allogeneic myocardium-derived mesenchymal stem cells for a total of 0.5 x 10\^7 cells. The injections will be administered following completion of CABG surgery.

  • BiologicalHB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)

    Biological: Higher dose of HB1011 injection Participants will receive between 5 intramyocardial injections of 2 million allogeneic myocardium-derived mesenchymal stem cells for a total of 1.0 x 10\^7 cells. The injections will be administered following completion of CABG surgery.

06

What researchers measure

Primary outcomes

  1. Adverse event, AE

    Treatment-Emergent Adverse Event, TEAE, Adverse Drug Reaction, ADR, Serious Adverse Event, SAE, Serious Adverse Drug Reaction, SADR, Suspected Unexpected Serious Adverse Drug Reaction, SUSAR

    Time frame: 12 Months

  2. DLT, Dose Limiting Toxicity

    DLT, Dose Limiting Toxicity

    Time frame: 12 Months

Secondary outcomes

  1. Change in LVEF by Echocardiography

    Change in left ventricular ejection fraction (LVEF) from baseline as measured by echocardiography

    Time frame: Baseline, 3, 6, and 12 months post-treatment

  2. Change in LVEF by Cardiac MRI

    Change in LVEF from baseline as measured by cardiac MRI

    Time frame: Baseline, 6, and 12 months post-treatment

  3. Change in Infarct Scar Size (ISS)

    Change in infarct scar size from baseline as measured by delayed contrast-enhanced cardiac MRI

    Time frame: Baseline, 6, and 12 months post-treatment

  4. Regional Wall Motion Abnormality (RWMA)

    Change in regional wall motion abnormality at the site of HB1011 injection as assessed by echocardiography

    Time frame: Baseline, 6, and 12 months post-treatment

  5. NYHA Functional Classification

    Change in NYHA functional class based on patient-reported activity limitation (Improved / Unchanged / Worsened)

    Time frame: Baseline, 1, 3, 6, 9, and 12 months post-treatment

  6. MACCE Incidence

    Composite rate of major adverse cardiac and cerebrovascular events including death, hospitalization for heart failure, non-fatal recurrent MI, target vessel revascularization, and stroke

    Time frame: Within 12 months post-treatment

  7. Mortality

    Proportion of patients who died following CABG surgery, categorized as early mortality (within 30 days), in-hospital mortality, and late mortality (after 30 days)

    Time frame: Within 12 months post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 16 months after the start.

Of 54 non-industry phase 1 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 16 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861035
Lead sponsor
HieraBio Inc.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Jun 23, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

HeeJung Kim, CTO
Contact
hierabio@hierabio.com
+82-711-7734

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion